∗Address for correspondence: Dr Michelle M. Kittleson, Cedars-Sinai Medical Center, 8670 Wilshir e Boulevard, 2nd Floor, Los Angeles, California 90211, USA. E-mail: E-mail Address: [email protected] Copyright © 2025, American College of Cardiology Foundation. Published by Elsevier Received March 10, 2025 Accepted March 18, 2025 Published online June 9,
AbstractBackgroundCardiovascular diseases (CVDs) are the leading cause of global mortality. Understanding epidemiologic trends in the modifiable risk factors driving CVDs is essential in designing …
AbstractBackgroundPostural orthostatic tachycardia syndrome (POTS) is a disorder characterized by orthostatic intolerance, tachycardia, and syncope. Ivabradine, though not Food and Drug Administrat…
View the JACC: Case Reports landing page, presenting the most recent and relevant articles on cardiovascular case reports.
AbstractBackgroundThe EVOQUE transcatheter tricuspid heart valve (Edwards Lifesciences) is approved for high-risk patients with severe tricuspid regurgitation (TR). This report describes the first …
AbstractBackgroundDiscordance between fractional flow reserve (FFR) and nonhyperemic pressure ratios (NHPRs) can occur in about 20% of clinical cases, creating treatment dilemmas in the cardiac…
AbstractBackgroundInflammation may play an important pathophysiological role in the development and progression of heart failure (HF). Interleukin (IL)-6 is a circulating cytokine and is the…
∗Address for correspondence: Dr Harlan M. Krumholz, Editor-in-Chief, JACC, Yale School of Medicine, 195 Church Street, Fifth Floor, New Haven, Connecticut 06510, USA. E-mail: E-mail…
AbstractBackgroundLeft ventricular pseudoaneurysm (LVPA) is a rare yet potentially life-threatening complication following myocardial infarction or cardiac surgery. Although surgical repair has tra…
AbstractBackgroundCardiovascular diseases (CVDs) are the leading cause of global mortality. Understanding epidemiologic trends in the modifiable risk factors driving CVDs is essential in designing …
Highlights •We developed a novel bispecific antibody, InflamAb, designed to target the IL-1R1 for cell entrance and inhibit the intracellular NLRP3 inflammasome.•InflamAb potently inhibits NLRP3…
